PMID- 11208898
OWN - NLM
STAT- MEDLINE
DCOM- 20020815
LR  - 20210105
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 76
IP  - 2
DP  - 2001 Jan
TI  - Group II metabotropic glutamate receptor activation protects striatal 
      dopaminergic nerve terminals against MPP+-induced neurotoxicity along with 
      brain-derived neurotrophic factor induction.
PG  - 351-60
AB  - We have studied the in vivo effect of the selective agonist for group II 
      metabotropic glutamate receptors (2S, 2'R, 
      3'R)-2-(2'3'-dicarboxycyclopropyl)glycine (DCG-IV) against MPP+-induced toxicity 
      on rat striatal dopaminergic nerve terminals by using both microdialysis and 
      immunohistochemical techniques. Perfusion of 1 mM DCG-IV during 1 h protected 
      dopaminergic nerve terminals against the degeneration induced by a 15-minute 
      perfusion of 1 mM MPP+. In addition, the microglial cell population was markedly 
      activated 24 h after DCG-IV perfusion. The astroglial cell population was only 
      markedly activated around the microdialysis probe. This protective effect seems 
      to be dependent on protein synthesis since 1 mM cycloheximide, an inhibitor of 
      protein synthesis, abolished the neuroprotective effect of 1 mM DCG-IV against 
      MPP+ toxicity. Perfusion of DCG-IV induced an upregulation of striatal 
      brain-derived neurotrophic factor (BDNF) mRNA expressing cells which were 
      confined precisely around the microdialysis probe. Taken together, our results 
      suggest that the induction and release of brain-derived neurotrophic factor 
      (BDNF) by activated glial cells induced by DCG-IV perfusion may account for its 
      protective action against MPP+-induced dopaminergic terminal degeneration.
FAU - Matarredona, E R
AU  - Matarredona ER
AD  - Departamento de Bioquimica, Bromatologia, Toxicologia y Medicina Legal, Facultad 
      de Farmacia, Universidad de Sevilla, Spain.
FAU - Santiago, M
AU  - Santiago M
FAU - Venero, J L
AU  - Venero JL
FAU - Cano, J
AU  - Cano J
FAU - Machado, A
AU  - Machado A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Benzoates)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cyclopropanes)
RN  - 0 (Dopamine Agents)
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Protein Synthesis Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Metabotropic Glutamate)
RN  - 146669-29-6 (alpha-methyl-4-carboxyphenylglycine)
RN  - 147782-19-2 (2-(2,3-dicarboxycyclopropyl)glycine)
RN  - 9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
RN  - TE7660XO1C (Glycine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MH  - Animals
MH  - Benzoates/pharmacology
MH  - Brain-Derived Neurotrophic Factor/genetics/metabolism
MH  - Corpus Striatum/cytology/drug effects/*metabolism
MH  - Cyclopropanes/pharmacology
MH  - Disease Models, Animal
MH  - Dopamine/analysis/metabolism
MH  - Dopamine Agents
MH  - Excitatory Amino Acid Agonists/*pharmacology
MH  - Excitatory Amino Acid Antagonists/pharmacology
MH  - Glycine/*analogs & derivatives/pharmacology
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - MPTP Poisoning/chemically induced/pathology/*prevention & control
MH  - Male
MH  - Microdialysis
MH  - Microglia/drug effects/metabolism/pathology
MH  - Neurons/drug effects/metabolism/pathology
MH  - Presynaptic Terminals/drug effects/*metabolism
MH  - Protein Synthesis Inhibitors/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Metabotropic Glutamate/agonists/*metabolism
EDAT- 2001/02/24 11:00
MHDA- 2002/08/16 10:01
CRDT- 2001/02/24 11:00
PHST- 2001/02/24 11:00 [pubmed]
PHST- 2002/08/16 10:01 [medline]
PHST- 2001/02/24 11:00 [entrez]
AID - 10.1046/j.1471-4159.2001.00056.x [doi]
PST - ppublish
SO  - J Neurochem. 2001 Jan;76(2):351-60. doi: 10.1046/j.1471-4159.2001.00056.x.